JP2011521968A - プリンｐｉ３ｋ阻害剤化合物および使用方法 - Google Patents

プリンｐｉ３ｋ阻害剤化合物および使用方法 Download PDF

Info

Publication number
JP2011521968A
JP2011521968A JP2011511842A JP2011511842A JP2011521968A JP 2011521968 A JP2011521968 A JP 2011521968A JP 2011511842 A JP2011511842 A JP 2011511842A JP 2011511842 A JP2011511842 A JP 2011511842A JP 2011521968 A JP2011521968 A JP 2011521968A
Authority
JP
Japan
Prior art keywords
purin
morpholino
cancer
alkylene
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521968A5 (OSRAM
Inventor
ジョーゼット カスタネド，
イリーナ チャコーリー，
エイドリアン フォルクス，
ダニエル ピー． サザーリン，
ナン チ ワン，
Original Assignee
ジェネンテック， インコーポレイテッド
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド, エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2011521968A publication Critical patent/JP2011521968A/ja
Publication of JP2011521968A5 publication Critical patent/JP2011521968A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011511842A 2008-05-30 2009-05-29 プリンｐｉ３ｋ阻害剤化合物および使用方法 Pending JP2011521968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5755908P 2008-05-30 2008-05-30
US61/057,559 2008-05-30
PCT/US2009/045603 WO2009146406A1 (en) 2008-05-30 2009-05-29 Purine pi3k inhibitor compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2011521968A true JP2011521968A (ja) 2011-07-28
JP2011521968A5 JP2011521968A5 (OSRAM) 2012-07-12

Family

ID=41017038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511842A Pending JP2011521968A (ja) 2008-05-30 2009-05-29 プリンｐｉ３ｋ阻害剤化合物および使用方法

Country Status (14)

Country Link
US (2) US8158624B2 (OSRAM)
EP (1) EP2279188B1 (OSRAM)
JP (1) JP2011521968A (OSRAM)
KR (1) KR20110042153A (OSRAM)
CN (1) CN102105474B (OSRAM)
AU (1) AU2009251291B2 (OSRAM)
BR (1) BRPI0909614A2 (OSRAM)
CA (1) CA2721851A1 (OSRAM)
ES (1) ES2533788T3 (OSRAM)
IL (1) IL208838A0 (OSRAM)
MX (1) MX2010012583A (OSRAM)
RU (1) RU2509081C2 (OSRAM)
WO (1) WO2009146406A1 (OSRAM)
ZA (1) ZA201007524B (OSRAM)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530903A (ja) * 2011-10-28 2014-11-20 ノバルティスアーゲー 新規プリン誘導体および疾患の処置におけるその使用
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
JP2016517872A (ja) * 2013-05-02 2016-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２受容体アゴニストとしてのプリン誘導体
JP2018510192A (ja) * 2015-04-02 2018-04-12 セロン ファーマ エス．アー．Ｃｅｌｏｎ Ｐｈａｒｍａ Ｓ．Ａ． 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体
JP2018521111A (ja) * 2015-04-21 2018-08-02 ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司Ｇｕｉｚｈｏｕ Ｂａｉｌｉｎｇ Ｅｎｔｅｒｐｒｉｓｅ Ｇｒｏｕｐ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101889015B (zh) 2007-10-05 2014-06-04 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
CA2701292C (en) * 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
CA2703138A1 (en) * 2007-10-26 2009-04-30 F. Hoffmann-La Roche Ag Purine derivatives useful as pi3 kinase inhibitors
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
MX358640B (es) 2008-01-04 2018-08-29 Intellikine Llc Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
MX2011010332A (es) 2009-04-03 2011-11-29 S Bio Pte Ltd Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
EP2451811A1 (en) * 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2761445A1 (en) * 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
BR112012011147A2 (pt) * 2009-11-12 2021-09-08 F.Hoffmann-La Roche Ag Composto, composição farmacêutica e uso de um composto.
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CN103003279B (zh) 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法
ES2612503T3 (es) * 2010-09-14 2017-05-17 Exelixis, Inc. Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
EP3053925A1 (en) * 2010-12-16 2016-08-10 F. Hoffmann-La Roche AG Tricyclic pi3k inhibitor compounds and methods of use
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
JP2014529298A (ja) * 2011-07-28 2014-11-06 ジェネンテック， インコーポレイテッド Ｐｉｋ３ｃａｈ１０４７ｒノックイン非ヒト動物乳癌モデル
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US20150011569A1 (en) * 2011-12-15 2015-01-08 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
CN105102000B (zh) 2012-11-01 2021-10-22 无限药品公司 使用pi3激酶亚型调节剂的癌症疗法
CN103936742B (zh) * 2013-01-17 2017-05-03 程鹏 含嘌呤基的新型pi3k抑制剂及其制备方法和应用
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104557872B (zh) * 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
CN103804380B (zh) * 2014-01-24 2016-05-18 温州医科大学 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10172942B2 (en) * 2014-12-17 2019-01-08 Pfizer Inc. Formulations of a PI3K/mTor-inhibitor for intravenous administration
TWI689508B (zh) 2015-03-30 2020-04-01 日商第一三共股份有限公司 可作爲ｐｉ３ｋ抑制劑之吡唑衍生物及其用途
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3521290A4 (en) * 2016-09-29 2020-04-22 Daiichi Sankyo Company, Limited CRYSTALS OF [2- (1-METHYL-1H-PYRAZOL-4-YL) -6- (MORPHOLIN-4-YL) -9H-PURIN-8-YL] [4- (MORPHOLIN-4-YL) PIPERIDIN-1 -YL] METHANONE AND PHARMACEUTICAL SAFE SALT THEREOF
KR102399639B1 (ko) 2016-12-02 2022-05-18 다이이찌 산쿄 가부시키가이샤 신규 엔도-β-N-아세틸글루코사미니다아제
AU2019345706B2 (en) * 2018-09-27 2024-02-22 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
CN111875606B (zh) * 2020-07-20 2023-04-07 武汉工程大学 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522209A (ja) * 2007-03-21 2010-07-01 ワイス エルエルシー ＰＩ３キナーゼおよびｍＴＯＲの阻害剤としてのイミダゾロピリミジン類似体およびその使用
JP2011500775A (ja) * 2007-10-26 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
JP2005504789A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌治療のための２−アロイルイミダゾール化合物
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
AU2002342051B2 (en) 2001-10-12 2009-06-11 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
AU2002357295A1 (en) * 2001-12-18 2003-06-30 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) * 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
US7122665B2 (en) 2002-10-15 2006-10-17 Synta Pharmaceuticals Corp. Heterocyclic compounds
TW200510394A (en) 2003-05-29 2005-03-16 Synta Pharmaceuticals Corp Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
JP5703432B2 (ja) * 2007-03-28 2015-04-22 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
EP2142545A1 (en) * 2007-03-28 2010-01-13 NeuroSearch A/S Purinyl derivatives and their use as potassium channel modulators
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
MX2011010332A (es) * 2009-04-03 2011-11-29 S Bio Pte Ltd Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
EP2451811A1 (en) * 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2761445A1 (en) * 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
CN103003279B (zh) * 2010-07-14 2015-09-23 弗·哈夫曼-拉罗切有限公司 对PI3K P110δ具有选择性的嘌呤化合物及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522209A (ja) * 2007-03-21 2010-07-01 ワイス エルエルシー ＰＩ３キナーゼおよびｍＴＯＲの阻害剤としてのイミダゾロピリミジン類似体およびその使用
JP2011500775A (ja) * 2007-10-26 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530903A (ja) * 2011-10-28 2014-11-20 ノバルティスアーゲー 新規プリン誘導体および疾患の処置におけるその使用
JP2016517872A (ja) * 2013-05-02 2016-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２受容体アゴニストとしてのプリン誘導体
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
JP2018510192A (ja) * 2015-04-02 2018-04-12 セロン ファーマ エス．アー．Ｃｅｌｏｎ Ｐｈａｒｍａ Ｓ．Ａ． 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体
JP2018521111A (ja) * 2015-04-21 2018-08-02 ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司Ｇｕｉｚｈｏｕ Ｂａｉｌｉｎｇ Ｅｎｔｅｒｐｒｉｓｅ Ｇｒｏｕｐ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤
JP7630502B2 (ja) 2019-10-09 2025-02-17 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Also Published As

Publication number Publication date
ZA201007524B (en) 2012-01-25
RU2509081C2 (ru) 2014-03-10
IL208838A0 (en) 2011-01-31
RU2010154428A (ru) 2012-07-10
AU2009251291B2 (en) 2013-05-02
US8158624B2 (en) 2012-04-17
KR20110042153A (ko) 2011-04-25
WO2009146406A1 (en) 2009-12-03
BRPI0909614A2 (pt) 2015-09-22
AU2009251291A1 (en) 2009-12-03
EP2279188B1 (en) 2015-01-28
ES2533788T3 (es) 2015-04-14
US8445487B2 (en) 2013-05-21
CN102105474B (zh) 2014-01-08
EP2279188A1 (en) 2011-02-02
CA2721851A1 (en) 2009-12-03
US20090318411A1 (en) 2009-12-24
CN102105474A (zh) 2011-06-22
US20120135988A1 (en) 2012-05-31
MX2010012583A (es) 2011-02-24

Similar Documents

Publication Publication Date Title
US8445487B2 (en) Purine PI3K inhibitor compounds and methods of use
JP5608099B2 (ja) ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5736171B2 (ja) チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5775171B2 (ja) 三環系ｐｉ３ｋ阻害剤化合物及びその使用方法
JP5689069B2 (ja) ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
JP6022691B2 (ja) ジオキシノ−及びオキサジン−［２，３−ｄ］ピリミジンｐｉ３ｋ阻害剤化合物及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140527